Recombinant human alpha galactosidase A

Drug Profile

Recombinant human alpha galactosidase A

Alternative Names: GC1119

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Carminatives; Enzymes; Recombinant proteins
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fabry's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Fabry's-disease in South Korea (IV, Infusion)
  • 26 Jul 2013 Phase-I development is ongoing in South Korea
  • 30 Jul 2012 Phase-I clinical trials in Fabry's disease in South Korea (IV) (NCT01653444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top